Abstract
Gastrointestinal stromal tumors (GIST) are the most common sarcomas of the gastrointestinal tract. Most are located in the stomach. This chapter describes management of GIST of the stomach, including resection. Preoperative preparation, pitfalls and danger points, documentation, and postoperative care are detailed. Surgical strategy and operative technique are described.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–5.
Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY, Group EGW. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):64–7.
Chen K, Zhou YC, Mou YP, Xu XW, Jin WW, Ajoodhea H. Systematic review and meta-analysis of safety and efficacy of laparoscopic resection for gastrointestinal stromal tumors of the stomach. Surg Endosc. 2015;29(2):355–67.
Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097–104.
DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258(3):422–9.
DeMatteo RP, Lewis JJ, Leung D, Mundan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8.
Eckardt AJ, Jenssen C. Current endoscopic ultrasound-guided approach to incidental subepithelial lesions: optimal or optional? Ann Gastroenterol. 2015;28(2):160–72.
Fairweather M, Balachandran VP, Li GZ, et al. Cytoreductive surgery for metastatic gastrointestinal stromal Tumors treated with tyrosine kinase inhibitors: a 2-institutional analysis. Ann Surg. 2017.
Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244(2):176–84.
Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012b;307(12):1265–72.
Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant Imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016;34(3):244–50.
Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012a;13(3):265–74.
Kang YK, Ryu MH, Yoo C, et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1175–82.
Karakousis GC, Singer S, Zheng J, et al. Laparoscopic versus open gastric resections for primary gastrointestinal stromal tumors (GISTs): a size-matched comparison. Ann Surg Oncol. 2011;18(6):1599–605.
Lamba G, Gupta R, Lee B, Ambrale S, Liu D. Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol. 2012;1(1):14.
McCarter MD, Antonescu CR, Ballman KV, et al. Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 2012;215(1):53–9. discussion 59-60
Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin N Am. 2013;42(2):399–415.
Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19:3–14.
Nishida T, Doi T, Naito Y. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Expert Opin Pharmacother. 2014;15(14):1979–89.
Philipper M, Hollerbach S, Gabbert HE, et al. Prospective comparison of endoscopic ultrasound-guided fine-needle aspiration and surgical histology in upper gastrointestinal submucosal tumors. Endoscopy. 2010;42(4):300–5.
Schmidt A, Bauder M, Riecken B, Caca K. Endoscopic resection of subepithelial tumors. World J Gastrointest Endosc. 2014;6(12):592–9.
Xiong H, Wang J, Jia Y, et al. Laparoscopic surgery versus open resection in patients with gastrointestinal stromal tumors: an updated systematic review and meta-analysis. Am J Surg. 2017.
Ye LP, Yu Z, Mao XL, Zhu LH, Zhou XB. Endoscopic full-thickness resection with defect closure using clips and an endoloop for gastric subepithelial tumors arising from the muscularis propria. Surg Endosc. 2014;28(6):1978–83.
Zhi X, Jiang B, Yu J, et al. Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:21541.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Won, E.J., Smith, B.R. (2022). Management of Gastrointestinal Stromal Tumor of the Stomach. In: Scott-Conner, C.E.H., Kaiser, A.M., Nguyen, N.T., Sarpel, U., Sugg, S.L. (eds) Chassin's Operative Strategy in General Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-81415-1_35
Download citation
DOI: https://doi.org/10.1007/978-3-030-81415-1_35
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-81414-4
Online ISBN: 978-3-030-81415-1
eBook Packages: MedicineMedicine (R0)